News | September 03, 2025
Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Subscribe To Our Newsletter & Stay Updated
